KRAS Mutations in Non-Small Cell Lung Cancer
Gregory J. Riely, J. Marks, William J. Pao · Proceedings of the American Thoracic Society · 2009
Some non-small cell lung cancers (NSCLCs) harbor a single specific mutated oncogene that is thought to be the primary genetic "driver" leading to cancer. The two most commonly mutated oncogenes in lung cancer encode for the epidermal growth factor receptor (EGFR) and KRAS. EGFR kinase domain mutations were only recently identified, but they have already been established in the clinic as valid predictors of increased sensitivity to EGFR kinase inhibitors (gefitinib and erlotinib). By contrast, even though KRAS mutations were identified in NSCLC tumors more than 20 years ago, we have only just begun to appreciate the clinical value of KRAS tumor status. Recent studies indicate that patients with mutant KRAS tumors fail to benefit from adjuvant chemotherapy, and their disease does not respond to EGFR inhibitors. There is a dire need for therapies specifically for patients with KRAS mutant NSCLC. In this review, we summarize the initial discovery of RAS mutations in NSCLC, describe work exploring associations with clinical factors and outcomes, and provide an overview of current approaches to targeting KRAS mutant NSCLC.
Cited by 549 works. doi:10.1513/pats.200809-107lc
Authors
References
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Mechanism of activation of a human oncogene
- A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene
- ras oncogenes in human cancer: a review.
- The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes
- Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts
- Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells
- Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change
- An Unidentified Virus which causes the Rapid Production of Tumours in Mice
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib